Indacaterol/glycopyrronium bromide: Phase III data

Top-line data from the 52-week, double-blind, international Phase III ENLIGHTEN trial in 339 patients with moderate to severe COPD showed that once-daily QVA149 met the primary safety endpoint vs. placebo. Specifically, QVA149 was well tolerated with a safety and tolerability profile similar to that of placebo. The Phase III IGNITE program of QVA149 consists of 10 trials, including the ENLIGHTEN trial. Last week, the partners also reported top-line data from the Phase III BRIGHT and SHINE trials. The Phase III ILLUMINATE trial comparing QVA149 vs. Advair fluticasone propionate/salmeterol is expected to be completed this quarter, while completion of the SPARK, BLAZE and ARISE trials is expected this year. ...